**Operations Guide for Pfizer Private Vaccination Programme (PVP)**

**[Note: This applies to only** **Pfizer-BioNTech/Comirnaty XBB.1.5 Monovalent Vaccine for individuals aged 6 months old and above]**

**Updated as of 21 May 2024**

1. VACCINATION ELIGIBILITY FOR PFIZER PVP
2. From 1 Apr 2024, **the Pfizer PVP has been extended to individuals aged 6 months and above. These individuals include Singapore Citizens, Permanent Residents and Long-Term Visit Pass holders who opt to take COVID-19 vaccine doses outside of the National Vaccination Programme (NVP). Under the PVP, doctors should assess a patient’s suitability for vaccination, exercise clinical judgement whether to proceed with the vaccination, and if so, counsel the patients on the risk-benefits of vaccinations.** Doctors **must continue to adhere** to HSA’s approved age indication for the Pfizer-BioNTech/Comirnaty XBB.1.5 monovalent vaccine.
3. The COVID-19 vaccinations received under the PVP is a private arrangement between the vaccinated person and his/her attending doctor, and such vaccinations would **not** be eligible for the Vaccine Injury Financial Assistance Programme (VIFAP). Patients must be counselled accordingly.
4. Providers may refer to the latest MOH medical circulars on COVID-19 vaccination for reference on the prevailing national COVID-19 vaccination recommendations but need not adhere to the age-band recommendations for PVP. **If a COVID-19 vaccine dose is provided with deviation from national recommendations and used “off-label”, doctors should ensure that it is in the patients’ best interest, that the risks and benefits of doing so are assessed and patients’ consent to this has been obtained.**
5. VACCINATION GUIDANCE FOR PFIZER
6. The Pfizer-BioNTech/Comirnaty XBB.1.5 monovalent vaccine will replace previous versions of Pfizer-BioNTech/Comirnaty vaccines for the primary vaccination series and additional dose vaccination, as indicated in the table below. Prevailing vaccination recommendations will apply. **With effect from 1 March 2024, individuals who have not been vaccinated against COVID-19 are now recommended to receive two initial vaccine doses.** Please note the changes in the concentration of the vaccine preparation, the dosing of the primary series vaccination and vaccine volumes.

a) 6 months to 4 years

|  |  |  |
| --- | --- | --- |
| **Vaccine** | **Eligible Age** | **Dose(s) and Recommended Intervals** |
| Pfizer-BioNTech/Comirnaty XBB.1.5 monovalent COVID-19 Vaccine | 6 months to 4 years | Primary series vaccination   * **2** doses of 3mcg (0.2mL) * 8 weeks apart |
| 2023/2024 additional dose   * 1 dose of 3mcg (0.2mL) * 1 year after last dose received |

b) 5 years to 11 years

|  |  |  |
| --- | --- | --- |
| **Vaccine** | **Eligible Age** | **Dose(s) and Recommended Intervals** |
| Pfizer-BioNTech/Comirnaty XBB.1.5 monovalent COVID-19 Vaccine[[1]](#footnote-1) | 5 to 11 years | Primary series vaccination   * **2** doses of 10mcg (0.3mL) * 8 weeks apart |
| 2023/2024 additional dose vaccination   * 1 dose of 10 mcg (0.3mL) * 1 year after the last dose |

c) 12 years and above

|  |  |  |
| --- | --- | --- |
| **Vaccine** | **Eligible Age** | **Dose(s) and Recommended Intervals** |
| Pfizer-BioNTech/Comirnaty XBB.1.5 monovalent COVID-19 Vaccine[[2]](#footnote-2) | ≥ 12 years | Primary series vaccination   * **2** doses of 30mcg (0.3mL) * 8 weeks apart |
| 2023/2024 additional dose vaccination   * 1 dose of 30 mcg (0.3mL) * 1 year after last dose received |

1. The EC19V has updated its recommendation to advise that individuals should receive an additional dose in 2023/2024, around one year (and no earlier than five months) after their last vaccine dose.
2. The additional dose is recommended for those at greatest risk of severe disease, including persons aged 60 years and above, medically vulnerable individuals and residents of aged care facilities. Beyond this group, the EC19V encourages all individuals aged 6 months and above to also receive the additional dose for 2023/2024, particularly for healthcare workers and household members/ caregivers of medically vulnerable individuals (See Annex).
3. Information on dosage, administration, storage, and handling are included in the vaccine package insert below. Clinics should ensure that they are familiar with the materials before carrying out vaccinations.

|  |  |  |
| --- | --- | --- |
| **Document** | **Purpose of Document** | **Pfizer-BioNTech/Comirnaty XBB.1.5 Monovalent** |
| Vaccine Package Insert | Information to vaccination clinics and vaccinators on dosage, administration, storage, and handling |  |

1. ONBOARDING CRITERIA FOR PFIZER PVP
2. Clinics **must not be participating in the National Vaccination Programme** **(NVP)** in order to be eligible for the Pfizer PVP. Clinics must also fulfil all licensing terms and conditions for the provision of COVID-19 vaccinations.

1. BILLING POLICY OF PFIZER VACCINE AND STOCKS ORDERING WORKFLOW
2. From 1 February 2024, the Pfizer-BioNTech/Comirnaty XBB.1.5 (5yr to 11yr formulation and 12yr above formulation) monovalent vaccine will be billed at **S$324.00 per vial (before GST)** and Pfizer-BioNTech/Comirnaty XBB.1.5 6mth to 4yr formulation will be billed at **$540 per vial (before GST)** to all participating private clinics and hospitals. Private clinics and hospitals will use their own IT system for bookings and charging, and strongly encouraged to input vaccination records into the National Immunisation Registry (NIR) for all vaccinations done **within 48 hours**. The clinics and hospitals may set their own price[[3]](#footnote-3), after accounting for their other costs and overheads. Stocks delivered are non-returnable and non-exchangeable. Please exercise prudence in your orders.
3. Orders should be placed via email to Zuellig Pharma using the purchase order form attached. For enquires on setting up business account with Zuellig Pharma or orders, please contact Zuellig Pharma at [sgzpscallcentermailbox@zuelligpharma.com](mailto:sgzpscallcentermailbox@zuelligpharma.com). Refer to **Table 1** for order cut-off time and delivery schedule. The **minimum order is 2 vials** of Pfizer vaccine. Additional charges apply for urgent same day delivery and after office hour delivery.

**Table 1:** Order cut-off time and delivery schedule

|  |  |
| --- | --- |
| **Order Placed on Working Day** | **Expected Vaccine Delivery**  **(9am – 12pm or 2pm – 5pm)** |
| Day 1; Before 10am | By Day 4; Within 3 working days |
| Day 1; After 10am  *(processed on next working day; Day 2)* | By Day 5; Within 4 working days |
| Orders placed on Friday or Eve of Public Holiday; Before 10am | Next 3 working days |
| *Note:*   1. *Place order using the purchase order form attached (please use the updated form)*  |  |  | | --- | --- | | *12yr and above formulation* |  | | *5yr to 11yr formulation* |  | | *6mth to 4yr formulation* |  |  1. *No order processing on Weekends and Public Holidays* 2. *There will be additional charge if clinic requests for urgent same day delivery* 3. *Vaccine shelf-life upon delivery is at least 7 weeks* | |

1. If you need any clarifications, feel free to contact the following officers below:

|  |  |  |  |
| --- | --- | --- | --- |
| **Topics for clarification** | **Division** | **Officer name** | **Email** |
| Matters regarding placing orders | Strategic Resource Management Division | Ivan Teo | [Ivan\_YL\_TEO@moh.gov.sg](mailto:Ivan_YL_TEO@moh.gov.sg)  cc: [MOH\_SRMD\_Supply@moh.gov.sg](mailto:MOH_SRMD_Supply@moh.gov.sg) |

1. Thank you.

**Annex**

|  |  |
| --- | --- |
| **Latest MOH Circular No. 12 released on 29 February 2024: CHANGES TO COVID-19 VACCINATION PRECAUTIONS AND**  **RECOMMENDATIONS** |  |

1. Vaccine dose of the Pfizer-BioNTech/Comirnaty XBB.1.5 monovalent COVID-19 vaccine to be used for primary series vaccination in individuals ages 5 to 11 years is 10 mcg (0.3 mL), the same as that used for the additional dose. [↑](#footnote-ref-1)
2. Vaccine dose of the Pfizer-BioNTech/Comirnaty XBB.1.5 monovalent vaccine to be used for primary series vaccination in individuals aged 12 years and older is 30 mcg (0.3 mL), the same as that used for the additional dose. [↑](#footnote-ref-2)
3. For individuals under the Private-Paid Vaccination Programme. All individuals eligible under the National Vaccination Programme should continue to receive Government-subsidised vaccinations at Joint Testing and Vaccination Centres or clinics participating in the National Vaccination Programme. [↑](#footnote-ref-3)